CRISPR Therapeutics (CRSP) to Release Earnings on Tuesday

CRISPR Therapeutics (NASDAQ:CRSP) is anticipated to post its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect the company to announce earnings of ($1.16) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 4:00 PM ET.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.15. The business had revenue of $0.89 million during the quarter, compared to the consensus estimate of $8.74 million. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $48.74 on Friday. The firm’s fifty day simple moving average is $54.74 and its 200-day simple moving average is $57.87. CRISPR Therapeutics has a 12 month low of $30.04 and a 12 month high of $78.48. The stock has a market capitalization of $4.64 billion, a price-to-earnings ratio of -8.72 and a beta of 1.72.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Bank of America reduced their target price on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a report on Thursday, January 22nd. Wells Fargo & Company set a $75.00 price objective on CRISPR Therapeutics in a research note on Monday, October 13th. Robert W. Baird decreased their price objective on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Needham & Company LLC reissued a “buy” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 23rd. Finally, Citigroup reaffirmed a “market outperform” rating on shares of CRISPR Therapeutics in a report on Friday, January 30th. Twelve analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus target price of $67.85.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 60,000 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total transaction of $3,613,800.00. Following the transaction, the chief executive officer owned 134,201 shares of the company’s stock, valued at $8,082,926.23. This represents a 30.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 4.30% of the stock is currently owned by company insiders.

Institutional Trading of CRISPR Therapeutics

A number of institutional investors have recently bought and sold shares of CRSP. Strategic Wealth Investment Group LLC acquired a new position in shares of CRISPR Therapeutics in the second quarter valued at approximately $36,000. Daiwa Securities Group Inc. grew its stake in CRISPR Therapeutics by 538.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,800 shares of the company’s stock worth $88,000 after acquiring an additional 1,518 shares during the period. Moneta Group Investment Advisors LLC acquired a new position in CRISPR Therapeutics in the 3rd quarter valued at $236,000. Prudential Financial Inc. acquired a new position in CRISPR Therapeutics in the 2nd quarter valued at $237,000. Finally, Corient Private Wealth LLC purchased a new position in shares of CRISPR Therapeutics during the 2nd quarter worth $246,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.